Hassan Fred 4

What Happened

• Fred Hassan, a director of BridgeBio Pharma, received equity awards on 2026-06-22 totaling 9,267 restricted stock units (RSUs). The filing shows two grant lines: 3,990 shares reported as acquired and 5,277 reported as a derivative acquisition; both at $0.00 (no cash paid).
• These RSUs represent contingent rights to receive common stock (each RSU = one share upon settlement) and do not reflect an immediate cash transaction or open-market purchase/sale.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (timely).
• Reported items: 3,990 RSUs (non-derivative) + 5,277 RSUs (derivative) = 9,267 total RSUs; price listed $0.00.
• Vesting: RSUs vest in full on June 22, 2027, subject to Hassan’s continued service on the board (per footnotes).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1/F2/F3 explain grants are RSUs under the 2021 incentive plan, each RSU equals one contingent share, and vesting is 6/22/2027. Exhibit 24 (Power of Attorney) included.
• No tax withholding, sale, exercise, or 10b5-1 plan noted in this filing.

Context

• This is an equity award (A = Award/Grant), a common form of director compensation that vests over time and does not imply an immediate purchase or sale. For retail investors, awards signal future potential dilution if and when RSUs settle into shares, but they are not an indication of buy/sell intent by the insider today.